Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials.

Abstract

BACKGROUND AND OBJECTIVE:

Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K(2)) against non-vertebral and hip fractures in patients with neurological diseases.

METHODS:

A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed.

RESULTS:

Three RCTs of patients with Alzheimer's disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment.

CONCLUSION:

The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.

• Authors: Jun Iwamoto, Hideo Matsumoto, Tsuyoshi Takeda
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 29 Issue 7 Pg. 471-479 ( 2009) ISSN: 1173-2563 [Print] New Zealand
• PMID: 19499964 (Publication Type: Journal Article, Meta-Analysis, Review, Retracted Publication)

Chemical References

• Bone Density Conservation Agents
• Vitamin K 2
• menatetrenone

Topics

• Aged
• Bone Density Conservation Agents (therapeutic use)
• Brain Diseases (complications)
• Female
• Fractures, Bone (complications, drug therapy)
• Hip Fractures (complications, drug therapy)
• Humans
• Male
• Randomized Controlled Trials as Topic
• Vitamin K 2 (analogs & derivatives, therapeutic use)